Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 =50% who progress on first-line immunotherapy: real-world data from a European cohort.
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 =50% who progress on first-line immunotherapy: real-world data from a European cohort. J Thorac Dis. 2019 Dec; 11(12):4972-4981.